Trial Profile
Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation: a Prospective, Multicenter, Cohort Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jan 2024
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Stroke
- Focus Adverse reactions
- Acronyms ERSAF
- 30 Dec 2023 Planned End Date changed from 30 Sep 2023 to 30 Jun 2024.
- 30 Dec 2023 Planned primary completion date changed from 30 Sep 2023 to 30 Jun 2024.
- 13 Jan 2023 Planned End Date changed from 30 Dec 2022 to 30 Sep 2023.